CBER Director Peter Marks (Susan Walsh/AP Images)
Thousands of gene and cell therapies are inundating FDA reviewers as the agency tries to keep up
The FDA’s staff is flooded with thousands of cell and gene therapy trials making their way through a short-handed regulatory workforce.
While the FDA has …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
